Henri-Jean Aubin is Professor of Psychiatry and Addictology at Hôpital Pitié-Salpétrière in Paris, France. He was the Principal Investigator in KT-110 phase 2 trial.

Karl Mann is Professor Emeritus at Central Institute of Mental Health, University of Heidelberg, Germany.

Wim van den Brink is Professor Emeritus of Psychiatry and Addiction at Academic Medical Center, University of Amsterdam, The Netherlands.

Antoni Gual is Head of the Addictions Unit Neurosciences Institute at University of Barcelona, Spain.

Raymond Anton is Professor Emeritus of Psychiatry and Addictions at Medical University of South Carolina, USA.

Within the scope of ECNP’s New Medications Symposium, Prof Henri-Jean Aubin and Julien Guiraud were invited to present results of phase 2 clinical trials.

The annual ECNP Congress is Europe’s premier scientific meeting for disease-oriented brain research.

Prof Henri-Jean Aubin was Principal Investigator for phase 2 clinical trial.

Julien Guiraud (Vergio Consulting) is co-author of phase 2 clinical trial publication.